NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Savara securitie ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Savara (SVRA) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder ri ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors, following a significant stock price drop after negative FDA news [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Savara Inc. and is looking into claims of securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Stock Performance - On May 27, 2025, Savara announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, leading to a stock price decline of $0.90 per share, or 31.69%, closing at $1.94 per share [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors following a significant stock price drop after an FDA refusal letter [1][3]. Group 1: Company Overview - Savara Inc. is a publicly traded company on NASDAQ under the ticker SVRA [1]. - The company recently announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, a therapy aimed at treating autoimmune PAP [3]. Group 2: Stock Performance - Following the FDA news, Savara's stock price decreased by $0.90 per share, representing a decline of 31.69%, closing at $1.94 per share on May 27, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation into Savara's potential misconduct [1][4]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. following a significant stock price drop after the FDA's refusal to file letter regarding its drug application [1][3]. Company Summary - Savara Inc. received a refusal to file letter from the FDA for its Biologics License Application for MOLBREEVI, intended to treat autoimmune PAP [3]. - Following this announcement, Savara's stock price decreased by $0.90, representing a 31.69% decline, closing at $1.94 per share on May 27, 2025 [3]. Legal Investigation - Pomerantz LLP is representing investors of Savara and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1].

Core Points - Savara Inc. received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, intended for treating autoimmune pulmonary alveolar proteinosis [1] - Following the FDA's decision, Savara's stock price experienced a decline [1] Company Information - Holzer & Holzer, LLC is investigating whether Savara complied with federal securities laws in light of the recent FDA decision [1] - The law firm specializes in representing shareholders and investors in litigation, including class action and derivative litigation, and has recovered hundreds of millions of dollars for affected shareholders since its founding in 2000 [3]